InsidersTradesSigma
Follow the 瑞康医药 stock price and the full directors' dealings record of the company, a listed equity based in China. Shares are quoted on the CN market, under the supervision of SSE / SZSE (CSRC). Operating in the Health Care sector, 瑞康医药 has logged 6 public disclosures. Market capitalisation: €4.1bn. The latest transaction was filed on 21 June 2024 (Purchase). Among the most active insiders: 张仁华. Every trade is accessible without an account.
6
Insider Decl.
n/a
Thresholds
€772,687
1 ops.
Buy Volume
€28m
5 ops.
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,752 of 29,064 companies
23.5
score / 100
Value29
Quality18
FCF yld-0.3%
Earn yld0.4%
EV/EBITDA24.2x
ROE0.8%
Gross mgn11%
Net mgn0.2%
Debt/EBITDA12.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 June 2024
Declarations6 total
2,638,600 sharesA股XSHESZSE:173000007779437440
6 of 6 declarations
关于 瑞康医药
瑞康医药是一家专注于医疗保健和制药领域的公司，提供与医疗保健相关的产品和服务。该公司在 XSHE 市场上市。